Modified Polyvinyl Alcohol Embolic Microspheres for Drug Loading

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Unmodified polyvinyl alcohol embolic microspheres lack functional groups for effective drug loading and have high crystallinity, leading to poor swelling and drug delivery performance.

Innovation Solution

The method involves modifying polyvinyl alcohol by introducing sulfonic acid groups into its side chains through a series of chemical reactions, including the use of acryloyl or butylenoyl chloride and taurine, to create functionalized microspheres with improved drug loading capacity and swelling properties.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If polyvinyl alcohol is used to prepare embolic microspheres, then the microspheres are non-toxic and biocompatible, but they lack functional groups for effective drug loading

Engineering Contradiction:
ImprovebiocompatibilityVSAvoidfunctional group content
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The patent applies parameter changes by modifying the chemical structure of PVA through grafting small molecule functional groups (carboxyl, sulfonic acid, amino groups) onto the PVA chains. This changes the chemical parameters of the material while maintaining its biocompatibility, enabling drug loading capability without sacrificing the inherent safety of PVA microspheres.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates composite materials by combining PVA with small molecule functional groups through grafting. The resulting modified PVA contains both the biocompatible PVA backbone and the drug-loading functional groups, effectively merging the advantages of both components into a single functional material system.

Inventive Principle:
Principle #40Composite materials

2Ease of manufacture

If pure polyvinyl alcohol microspheres are used, then the material is simple and easy to manufacture, but the crystallinity is strong leading to slow swelling and poor drug delivery performance

Engineering Contradiction:
Improvemanufacturing simplicityVSAvoidswelling speed
Core Design Contradiction:
Ease of manufactureVSSpeed

Solution Approach 1:

The patent changes the physical-chemical parameters of PVA by introducing small molecule grafts that disrupt the crystalline structure. This reduces the crystallinity and increases the amorphous content, thereby accelerating water penetration and swelling speed while maintaining the basic microsphere formation process.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent applies local quality changes by introducing functional groups at specific locations along the PVA chains. These localized modifications create regions of reduced crystallinity and increased hydrophilicity, which serve as initiation points for rapid water absorption and swelling, while the overall microsphere structure remains intact.

Inventive Principle:
Principle #3Local quality

3Quantity of substance

If surface modification of blank PVA microspheres is performed, then functional groups are introduced, but the functional groups are located only on the surface with small numbers and strong internal crystallinity

Engineering Contradiction:
Improvefunctional group contentVSAvoidinternal crystallinity
Core Design Contradiction:
Quantity of substanceVSStability of the object's composition

Solution Approach 1:

The patent applies preliminary action by modifying the PVA chains before microsphere formation. The small molecule functional groups are grafted onto the PVA in solution, ensuring uniform distribution throughout the polymer chains before the microspheres are formed. This preliminary functionalization ensures that functional groups are present both on the surface and throughout the internal structure.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent transitions from surface-only modification to bulk modification by changing the dimension of functional group distribution. Instead of adding functional groups only to the surface (2D modification), the grafting occurs in the bulk solution phase, distributing functional groups throughout the 3D structure of the PVA chains, which then form microspheres with uniform internal functionalization.

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

4Quantity of substance

If crosslinkers with functional groups are used for copolymerization, then functional groups are introduced into polyvinyl alcohol, but the synthetic method becomes complex and functional group content remains low

Engineering Contradiction:
Improvefunctional group contentVSAvoidsynthetic method complexity
Core Design Contradiction:
Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent extracts the functionalization step from the polymerization process itself. Instead of using complex crosslinkers with functional groups during copolymerization, the method separates the processes: first forming simple PVA microspheres, then separately grafting small molecule functional groups onto the formed microspheres. This extraction simplifies the synthetic method while achieving high functional group content.

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent segments the modification process into distinct stages: (1) PVA microsphere formation, (2) functional group grafting onto surface and internal structures, and (3) drug loading. This segmentation allows each step to be optimized independently, achieving high functional group content without the complexity of simultaneous crosslinking and functionalization.

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified microspheres exhibit enhanced drug loading rates and speeds due to increased functional group density and reduced crystallinity, facilitating better drug release and delivery.

Implementation Method 1

modifying polyvinyl alcohol by introducing sulfonic acid groups into its side chains through a series of chemical reactions, including the use of acryloyl or butylenoyl chloride and taurine

Methodology Applied
Scientific EffectChemical Bonding: Chemical Bonding

Data Source

PatentUS20240108581A1Method for making modified polyvinyl alcohol embolic microsphere
Publication Date: 2024.04.04 JIANGNAN UNIV
  • US20240108581A1 patent drawing
  • US20240108581A1 patent drawing
  • US20240108581A1 patent drawing

AI summary

The invention provides a making method of modified polyvinyl alcohol embolic microspheres. First, polyvinyl alcohol dimethyl sulfoxide solution is added to acryloyl chloride dichloromethane solution for reaction, then taurine solution is added to the above solution for further reaction, so that functional groups are introduced into the side chains of polyvinyl alcohol, then blank microspheres are prepared by suspension crosslinking method, and finally, drug-loaded modified polyvinyl alcohol embolic microspheres are prepared. The invention aims at improving the drug loading rate and drug loading speed of the microspheres. Through modification, the crystallinity of polyvinyl alcohol is weakened, the swelling in water is accelerated, and the application effect of the microspheres is improved.